...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Myconostica Announces CE Marking of MycAssay Product Family on Additional Platforms

| Print |
Monday, 09 August 2010 11:00 (UTC + 2)

myconostica_logo_

Manchester, United Kingdom, August 9, 2010 / b3c newswire / - Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead products MycAssay™ Aspergillus and MycAssay™ Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000 series platforms.


The CE marking on these two platforms in addition to the existing CE marking on the Cepheid Smartcycler® and Applied Biosystems ABI 7500 means these products are now available on the four real-time PCR machines most common in clinical microbiology and mycology laboratories.

 

MycAssay™ Pneumocystis is a molecular diagnostic test for the detection of Pneumocystis jirovecii DNA in lower respiratory tract samples. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay™ Pneumocystis aid physicians to make a diagnosis in patients suspected of having an infection caused by Pneumocystis jirovecii.


MycAssay™ Aspergillus is a molecular diagnostic test for the detection of Aspergillus spp DNA in lower respiratory tract samples. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay™ Aspergillus aid physicians to make a diagnosis in patients suspected of having an infection caused by Aspergillus.


When used in conjunction with Myconostica's fungal DNA extraction system, MycXtra®, a result can be obtained within 3 hours of sample receipt. The MycAssay™ products provide rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.


Dr. John Thornback, Myconostica’s Chief Business Officer, said  “We are committed to developing diagnostics for  life threatening diseases and we are dedicated to making our products available to the widest possible customer base. We recognise that our customers in the clinical laboratories have multiple opportunities for real-time PCR platforms and so we have an intensive ongoing programme to adapt our assays to fit in with our customers. These latest CE marks are part of that successful programme".



About Myconostica Ltd. - www.myconostica.co.uk

Myconostica Ltd, a UK-based medical diagnostic company, specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow.  Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.
Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.
 

For further information please contact:

Myconostica Ltd
Heidi Wahlefeld-Moghimi
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)161 998 7239